bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common StockBusiness Wire • 12/20/23
bluebird bio stock rises on 2024 patient start guidance; commercial agreement for sickle cell therapyProactive Investors • 12/14/23
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb LevelsBusiness Wire • 12/10/23
Long-term Follow-up Data From bluebird's Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive EventsBusiness Wire • 12/09/23
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive EventsBusiness Wire • 12/08/23
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive EventsBusiness Wire • 12/08/23
Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/07/23